Teucrium Corn Fund vs Regeneron Pharmaceuticals Inc — how do they compare? Teucrium Corn Fund trades at $17.59, while Regeneron Pharmaceuticals Inc trades at $806.98 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Teucrium Corn Fund pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, Teucrium Corn Fund nearer its low. Which is the better fit depends on your goals.
| CORN | REGN | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $19.12 | $812.27 |
52-Week Low | $16.46 | $545.94 |
Market Cap | — | $83.19B |
Enterprise Value | — | $77.90B |
Dividend Yield | — | 0.47% |
Signals from Pluang's Aura AI — not financial advice
CORN trades at $17.64, up 0.17% for the day, with technical indicators showing a bearish bias from moving averages despite a neutral oscillator stance and oversold short-term RSI. Recent news highlights strong performance in agricultural ETFs, with CORN returning 9.7% over the past month, driven by inflation trends and geopolitical tensions affecting commodity markets.
The outlook is mixed; positive momentum from commodity strength offers upside, but bearish technicals and reliance on volatile agricultural markets pose risks. Investors should weigh near-term commodity tailwinds against the absence of fundamental financial data and broader market sentiment shifts.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Trailing returns across standard periods
Latest headlines on both assets
CORN is a commodity ETF that provides exposure to the price of corn futures. It uses a laddered investment strategy across multiple benchmark contracts to help minimize the impact of contango and roll costs in the agricultural market.
Read more on CORN →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →